Fusen Pharmaceutical Management

Management criteria checks 2/4

Fusen Pharmaceutical's CEO is Dudu Cao, appointed in Jan 2013, has a tenure of 11.83 years. total yearly compensation is CN¥5.00M, comprised of 32.4% salary and 67.6% bonuses, including company stock and options. directly owns 20.92% of the company’s shares, worth HK$139.19M. The average tenure of the management team and the board of directors is 5.6 years and 7.6 years respectively.

Key information

Dudu Cao

Chief executive officer

CN¥5.0m

Total compensation

CEO salary percentage	32.4%
CEO tenure	11.8yrs
CEO ownership	20.9%
Management average tenure	5.6yrs
Board average tenure	7.6yrs

Recent management updates

Recent updates

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

May 21

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Mar 31

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Feb 08

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Jan 18

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Dec 28

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Dec 07

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Nov 20

CEO Compensation Analysis

How has Dudu Cao's remuneration changed compared to Fusen Pharmaceutical's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-CN¥90m
Mar 31 2024	n/a	n/a	-CN¥63m
Dec 31 2023	CN¥5m	CN¥2m	-CN¥36m
Sep 30 2023	n/a	n/a	-CN¥24m
Jun 30 2023	n/a	n/a	-CN¥11m
Mar 31 2023	n/a	n/a	-CN¥23m
Dec 31 2022	CN¥2m	CN¥2m	-CN¥35m
Sep 30 2022	n/a	n/a	-CN¥34m
Jun 30 2022	n/a	n/a	-CN¥34m
Mar 31 2022	n/a	n/a	-CN¥9m
Dec 31 2021	CN¥2m	CN¥2m	CN¥17m
Sep 30 2021	n/a	n/a	CN¥48m
Jun 30 2021	n/a	n/a	CN¥79m
Mar 31 2021	n/a	n/a	CN¥75m
Dec 31 2020	CN¥2m	CN¥1m	CN¥70m
Sep 30 2020	n/a	n/a	CN¥67m
Jun 30 2020	n/a	n/a	CN¥65m
Mar 31 2020	n/a	n/a	CN¥59m
Dec 31 2019	CN¥548k	CN¥516k	CN¥53m
Sep 30 2019	n/a	n/a	CN¥63m
Jun 30 2019	n/a	n/a	CN¥72m
Mar 31 2019	n/a	n/a	CN¥87m
Dec 31 2018	CN¥251k	CN¥242k	CN¥102m

Compensation vs Market: Dudu's total compensation ($USD689.67K) is above average for companies of similar size in the Hong Kong market ($USD233.11K).

Compensation vs Earnings: Dudu's compensation has increased whilst the company is unprofitable.

CEO

Dudu Cao (38 yo)

11.8yrs

Tenure

CN¥4,997,000

Compensation

Mr. Zhiming Cao, also known as Dudu Cao is the Executive Director and Chief Executive Officer of Fusen Pharmaceutical Company Limited since January 18, 2013 and serves as its Chairman since November 04, 20...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Zhiming Cao	CEO & Executive Chairman	11.8yrs	CN¥5.00m	20.92% HK$ 139.2m
Taisheng Hou	Executive Director	no data	CN¥81.00k	no data
Yongsheng Chi	Executive Director	no data	CN¥78.00k	no data
Qingfen Meng	Executive Director	no data	CN¥62.00k	no data
Zhen Li	Chief Financial Officer	5.6yrs	no data	no data
Yuk Hong Yeung	Company Secretary	less than a year	no data	no data

5.6yrs

Average Tenure

52.5yo

Average Age

Experienced Management: 1652's management team is seasoned and experienced (5.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Zhiming Cao	CEO & Executive Chairman	11.8yrs	CN¥5.00m	20.92% HK$ 139.2m
Taisheng Hou	Executive Director	7.6yrs	CN¥81.00k	no data
Yongsheng Chi	Executive Director	7.6yrs	CN¥78.00k	no data
Qingfen Meng	Executive Director	7.6yrs	CN¥62.00k	no data
Kwok Tung Lee	Independent Non-Executive Director	5.6yrs	CN¥162.00k	no data
Wing Chun Sze	Independent Non-Executive Director	6.4yrs	CN¥162.00k	no data
Kit Wa To	Independent Non-Executive Director	4.3yrs	CN¥162.00k	no data

7.6yrs

Average Tenure

56yo

Average Age

Experienced Board: 1652's board of directors are considered experienced (7.6 years average tenure).

Fusen Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Fusen Pharmaceutical Company Limited, Annual General Meeting, May 28, 2024

CEO & Executive Director recently bought HK$224k worth of stock

Executive Chairman recently bought HK$84k worth of stock

CEO & Executive Director recently bought HK$1.0m worth of stock

Executive Chairman recently bought HK$1.1m worth of stock

Executive Chairman recently bought HK$918k worth of stock

Recent updates

Eltrombopag Olamine Tablets Developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Obtains the Approval for Marketing from the National Medical Products Administration of China

Fusen Pharmaceutical Company Limited Announces Acceptance of Application for Consistency Evaluation of Nicardipine Hydrochloride Injection

First half 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.022 profit in 1H 2023)

Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2024

Fusen Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 29, 2024

Fusen Pharmaceutical Company's Subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces Acceptance of Clinical Trial Application for ``SY617''

New minor risk - Market cap size

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Fusen Pharmaceutical Company Limited, Annual General Meeting, May 28, 2024

CEO & Executive Director recently bought HK$224k worth of stock

Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 loss in FY 2022)

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

Fusen Pharmaceutical Company Limited to Report Q2, 2023 Results on Aug 29, 2023

Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023

Executive Chairman recently bought HK$84k worth of stock

CEO & Executive Director recently bought HK$1.0m worth of stock

Full year 2022 earnings released: CN¥0.046 loss per share (vs CN¥0.022 profit in FY 2021)

Executive Chairman recently bought HK$1.1m worth of stock

Executive Chairman recently bought HK$918k worth of stock

CEO & Executive Director recently bought HK$375k worth of stock

Executive Chairman recently bought HK$791k worth of stock

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Executive Chairman recently bought HK$2.3m worth of stock

Less than half of directors are independent

CEO & Executive Director recently bought HK$2.2m worth of stock

Executive Chairman recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$658k worth of stock

CEO & Executive Director recently bought HK$79k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

First half 2022 earnings released: CN¥0.01 loss per share (vs CN¥0.057 profit in 1H 2021)

Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022

Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Fusen Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 29, 2022

CEO & Executive Director recently bought HK$157k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

Fusen Pharmaceutical Company Limited Declares Final Dividend for the Year Ended 31 December 2021

Less than half of directors are independent

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$856k worth of stock

CEO & Executive Director recently bought HK$2.1m worth of stock

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Fusen Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2020

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.089 (vs CN¥0.067 in FY 2019)

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS CN¥0.09 (vs CN¥0.067 in FY 2019)

Investor sentiment improved over the past week

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

New 90-day low: HK$4.17

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Company Secretary has left the company

Fusen Pharmaceutical Company Limited Announces Executive Changes, with Effect from 29 January 2021

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Investor sentiment deteriorated over the past week